🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 12 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
19/03/2024 17,16 17,66 17,03 17,30 +0,46% 3,67% 568.800
18/03/2024 18,92 18,98 17,16 17,22 -9,27% 9,62% 1.002.700
15/03/2024 18,20 19,18 18,09 18,98 +3,60% 6,02% 1.640.400
14/03/2024 18,77 18,93 18,03 18,32 -3,83% 4,79% 763.000
13/03/2024 18,57 19,13 18,57 19,05 +2,20% 3,02% 747.500
12/03/2024 18,95 19,01 18,27 18,64 -1,95% 3,91% 828.500
11/03/2024 18,05 19,35 18,05 19,01 +5,67% 7,20% 1.283.600
08/03/2024 18,19 18,50 17,76 17,99 +0,39% 4,07% 486.400
07/03/2024 19,43 19,69 17,86 17,92 -7,44% 9,41% 596.400
06/03/2024 19,00 19,44 18,64 19,36 +3,09% 4,18% 695.900
05/03/2024 18,81 19,13 18,51 18,78 -1,21% 3,30% 516.400
04/03/2024 19,36 19,36 18,50 19,01 -0,47% 4,44% 538.600
01/03/2024 19,20 19,60 18,95 19,10 -0,16% 3,39% 877.800
29/02/2024 19,55 20,00 19,00 19,13 -0,10% 5,12% 1.001.600
28/02/2024 19,88 20,11 19,13 19,15 -5,10% 4,90% 750.200
27/02/2024 19,71 20,31 19,49 20,18 +2,64% 4,16% 982.900
26/02/2024 19,50 20,17 19,28 19,66 +0,67% 4,56% 1.014.700
23/02/2024 19,51 19,68 18,80 19,53 -0,71% 4,51% 1.284.400
22/02/2024 17,00 19,96 16,97 19,67 +19,87% 17,59% 3.513.400
21/02/2024 16,39 16,61 16,07 16,41 -1,14% 3,29% 511.600
20/02/2024 16,55 17,04 15,93 16,60 -1,19% 6,71% 2.172.900
16/02/2024 16,15 16,89 16,03 16,80 +2,38% 5,33% 935.300
15/02/2024 16,13 16,51 15,98 16,41 +2,82% 3,29% 1.002.600
14/02/2024 15,48 16,08 15,27 15,96 +4,52% 5,23% 628.200
13/02/2024 15,77 15,85 15,13 15,27 -7,23% 4,57% 893.100
12/02/2024 16,13 16,91 15,91 16,46 +4,11% 6,20% 945.200
09/02/2024 15,30 16,12 15,22 15,81 +3,94% 5,90% 874.700
08/02/2024 14,83 15,32 14,74 15,21 +2,56% 3,91% 672.900
07/02/2024 15,31 15,31 14,76 14,83 -3,20% 3,59% 632.700
06/02/2024 15,16 15,61 15,13 15,32 +0,66% 3,17% 606.800